Glen I Spielmans1, Peter Parry2,3. 1. Department of Psychology Metropolitan State University Saint Paul Minnesota. 2. School of Clinical Medicine - Children's Health Queensland Unit University of Queensland Brisbane. 3. College of Medicine and Public Health Flinders University Adelaide South Australia.
In their article “Increases in suicide deaths among adolescents and young adults following US Food and Drug Administration antidepressant boxed warnings and declines in depression care” Lu et al. claimed that the suicidality Black Box Warning for antidepressants led to decreased treatment of depression, which caused a high number of excess suicides among adolescents and young adults in the United States (1).Treatment of youth depression has actually not substantially decreased since the Black Box warning. Lu et al. found a decrease in antidepressant treatment of less than one percentage point among children and adolescents from 2000 to 2010 (2). Kafali et al. found that antidepressant prescription rates for youth returned to prewarning levels by 2009 (3). Among parents who indicated that their child had severe impairment on the Columbia Impairment Scale, there was no decrease in antidepressant prescriptions after the warning. Valluri et al. examined changes in antidepressant prescribing from 2004 to 2006 and found that adolescents with major depressive disorder did not experience a decrease in antidepressant treatment (4). Rather, decreases in antidepressant prescribing occurred among those with major depression not otherwise specified and dysthymia diagnoses.Furthermore, Plöderl & Hengartner found a strong correlation between increased self‐reported antidepressant use and more self‐reported suicide attempts between 2004 and 2016 among adolescents (5). However, population‐wide associations between antidepressant prescribing and suicides cannot establish causality, due to an inability to control for extraneous variables which may influence suicide rates (6). There are better ways to demonstrate whether a drug causes suicidality, such as the placebo‐controlled trials that originally led to the FDA warning (7). In sum, the evidence does not support Lu et al.‘s (1) contention that regulatory warnings led to decreased treatment, which then led to increased suicides.
Authors: Satish Valluri; Julie M Zito; Daniel J Safer; Ilene H Zuckerman; C Daniel Mullins; James J Korelitz Journal: Med Care Date: 2010-11 Impact factor: 2.983
Authors: Christine Y Lu; Fang Zhang; Matthew D Lakoma; Jeanne M Madden; Donna Rusinak; Robert B Penfold; Gregory Simon; Brian K Ahmedani; Gregory Clarke; Enid M Hunkeler; Beth Waitzfelder; Ashli Owen-Smith; Marsha A Raebel; Rebecca Rossom; Karen J Coleman; Laurel A Copeland; Stephen B Soumerai Journal: BMJ Date: 2014-06-18